FLNA Stock Chart & Stats
$15.92
$0.00(0.00%)
At close: 4:00 PM EDT
$15.92
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.30 - $84.00
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$548.38M
Enterprise Value-$25.19M
Total Cash (Recent Filing)$82.68M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.17
Next Earnings
Nov 11, 2026EPS Estimate
-4.58Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.66
Shares Outstanding48,307,896
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)1.33
Price to Sales (P/S)0.00
P/FCF Ratio-3.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$120.60Price Target Upside657.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-16.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageNear-zero debt limits interest obligations and reduces refinancing pressure, giving Filana greater flexibility than a highly leveraged biotech. Although the company remains loss-making, its capital structure does not currently add substantial fixed financial claims to its operating burden.
Reduced Cash BurnThe sharp year-over-year reduction in operating cash outflow indicates materially better spending control or lower cash requirements in 2025. If sustained, this improvement could extend the company’s funding runway and reduce the pace at which external capital is required.
Clinical Development RestartRemoval of the full clinical hold restores the ability to advance simufilam into a defined Phase 2a study, while trial sites, investigators, drug supply, and a clinical research organization were prepared. This reopens a potential development pathway in refractory TSC epilepsy.
Bears Say
No Commercial RevenueA six-year record of zero revenue leaves Filana without a proven commercial funding engine, while the renewed 2025 loss shows that development spending remains substantial. Until a product is commercialized or partnered, earnings visibility depends heavily on future clinical progress.
Persistent Cash ConsumptionContinued negative operating and free cash flow means the business is not self-funding and must keep financing research and development through existing resources or external capital. This limits strategic flexibility and leaves the company exposed to funding pressure if losses persist.
Nasdaq Listing RiskThe minimum-bid deficiency creates a continuing listing-compliance burden through March 16, 2027, with potential further review and delisting risk if compliance is not restored. Losing the Nasdaq listing could impair market visibility and complicate access to public capital.
Filana Therapeutics News
FLNA FAQ
What was Filana Therapeutics’s price range in the past 12 months?
Filana Therapeutics lowest stock price was $11.30 and its highest was $84.00 in the past 12 months.
What is Filana Therapeutics’s market cap?
Filana Therapeutics’s market cap is $548.38M.
When is Filana Therapeutics’s upcoming earnings report date?
Filana Therapeutics’s upcoming earnings report date is Nov 11, 2026 which is in 14 days.
How were Filana Therapeutics’s earnings last quarter?
Filana Therapeutics released its earnings results on Aug 05, 2026. The company reported -$3.363 earnings per share for the quarter, beating the consensus estimate of -$4.204 by $0.841.
Is Filana Therapeutics overvalued?
According to Wall Street analysts Filana Therapeutics’s price is currently Undervalued.
Does Filana Therapeutics pay dividends?
Filana Therapeutics does not currently pay dividends.
What is Filana Therapeutics’s EPS estimate?
Filana Therapeutics’s EPS estimate is -4.58.
How many shares outstanding does Filana Therapeutics have?
Filana Therapeutics has 48,307,896 shares outstanding.
What happened to Filana Therapeutics’s price movement after its last earnings report?
Filana Therapeutics reported an EPS of -$3.363 in its last earnings report, beating expectations of -$4.204. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Filana Therapeutics?
Currently, no hedge funds are holding shares in MX:FLNA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Filana Therapeutics
Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.
FLNA Stock 12 Month Forecast
Average Price Target
$120.60
▲(657.57% Upside)